Stephan A Hahn

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7590977/stephan-a-hahn-publications-by-year.pdf

Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

130 papers **10,936** citations

46 h-index

104 g-index

144 ext. papers

11,960 ext. citations

7.6 avg, IF

5.41 L-index

#	Paper	IF	Citations
130	New Therapy Options for Neuroendocrine Carcinoma of the Pancreas The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo. <i>Cancers</i> , 2022 , 14, 2685	6.6	
129	TNF-Eproducing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer <i>Nature Cancer</i> , 2021 , 2, 1185-1203	15.4	3
128	Unveiling Luminescent Ir and Rh N-Heterocyclic Carbene Complexes: Structure, Photophysical Specifics, and Cellular Localization in the Endoplasmic Reticulum. <i>Chemistry - A European Journal</i> , 2021 , 27, 6783-6794	4.8	5
127	Deficiency of myostatin protects skeletal muscle cells from ischemia reperfusion injury. <i>Scientific Reports</i> , 2021 , 11, 12572	4.9	О
126	Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. <i>Gut</i> , 2021 , 70, 743-760	19.2	26
125	Disabling VEGF-Response of Purkinje Cells by Downregulation of via miRNA-204-5p. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
124	Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models. <i>Genome Medicine</i> , 2021 , 13, 116	14.4	3
123	Digital-Droplet PCR for Quantification of CD19-Directed CAR T-Cells. <i>Frontiers in Molecular Biosciences</i> , 2020 , 7, 84	5.6	11
122	TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer. <i>Cell Death Discovery</i> , 2020 , 6, 12	6.9	16
121	Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2020 , 147, 2847-2861	7.5	16
120	Metabolism-based GP-2250 in combination with gemcitabine as a novel approach to pancreatic cancer: A mouse xenograft study <i>Journal of Clinical Oncology</i> , 2020 , 38, e16750-e16750	2.2	3
119	Altered T-Lymphocyte Biology Following High-Dose Melphalan and Autologous Stem Cell Transplantation With Implications for Adoptive T-Cell Therapy. <i>Frontiers in Oncology</i> , 2020 , 10, 568056	5.3	3
118	Systematic Comparison of Label-Free, SILAC, and TMT Techniques to Study Early Adaption toward Inhibition of EGFR Signaling in the Colorectal Cancer Cell Line DiFi. <i>Journal of Proteome Research</i> , 2020 , 19, 926-937	5.6	17
117	Activation leads to a significant shift in the intracellular redox homeostasis of neutrophil-like cells. <i>Redox Biology</i> , 2020 , 28, 101344	11.3	8
116	Deregulated Correlates with Tissue-Specific Activation of Intrinsic Apoptosis in An Animal Model of Amyotrophic Lateral Sclerosis. <i>Cells</i> , 2019 , 8,	7.9	10
115	Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in -Mutant Pancreatic and Colorectal Cancer. <i>Cancer Research</i> , 2019 , 79, 2367-2378	10.1	31
114	Alterations in pectoralis muscle cell characteristics after radiation of the human breast in situ. <i>Journal of Radiation Research</i> , 2019 , 60, 825-830	2.4	4

(2015-2018)

113	MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS. <i>Journal of Neuro-Oncology</i> , 2018 , 137, 463-468	4.8	16
112	Exploring the efficacy and cellular uptake of sorafenib in colon cancer cells by Raman micro-spectroscopy. <i>Analyst, The</i> , 2018 , 143, 6069-6078	5	10
111	Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level. <i>Scientific Reports</i> , 2018 , 8, 15278	4.9	17
110	Unveiling of miRNA Expression Patterns in Purkinje Cells During Development. <i>Cerebellum</i> , 2017 , 16, 376-387	4.3	13
109	Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo. <i>BMC Cancer</i> , 2017 , 17, 216	4.8	3
108	Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. <i>Molecular Oncology</i> , 2017 , 11, 208-219	7.9	83
107	Asymmetric rhenium tricarbonyl complexes show superior luminescence properties in live cell imaging. <i>Chemical Communications</i> , 2017 , 53, 905-908	5.8	30
106	A genetic roadmap of pancreatic cancer: still evolving. <i>Gut</i> , 2017 , 66, 2170-2178	19.2	32
105	Activation of odorant receptor in colorectal cancer cells leads to inhibition of cell proliferation and apoptosis. <i>PLoS ONE</i> , 2017 , 12, e0172491	3.7	35
104	A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling. <i>Gut</i> , 2016 , 65, 647-57	19.2	40
103	Nuclear spheres modulate the expression of BEST1 and GADD45G. <i>Cellular Signalling</i> , 2016 , 28, 100-9	4.9	5
102	Long-noncoding RNAs in basal cell carcinoma. <i>Tumor Biology</i> , 2016 , 37, 10595-608	2.9	28
101	Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 795-805	4.9	27
100	Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma. <i>Neuro-Oncology</i> , 2016 , 18, 361-7	1	33
99	Circular RNA expression in cutaneous squamous cell carcinoma. <i>Journal of Dermatological Science</i> , 2016 , 83, 210-8	4.3	102
98	Expression profiles of long noncoding RNAs in cutaneous squamous cell carcinoma. <i>Epigenomics</i> , 2016 , 8, 501-18	4.4	23
97	Circular RNA expression in basal cell carcinoma. <i>Epigenomics</i> , 2016 , 8, 619-32	4.4	72
96	U2 Small Nuclear RNA as a Biomarker in Cancer. <i>Biomarkers in Disease</i> , 2015 , 233-250		

95	Label-Free Raman Spectroscopic Imaging Monitors the Integral Physiologically Relevant Drug Responses in Cancer Cells. <i>Analytical Chemistry</i> , 2015 , 87, 7297-304	7.8	50
94	MiR-93 Controls Adiposity via Inhibition of Sirt7 and Tbx3. <i>Cell Reports</i> , 2015 , 12, 1594-605	10.6	82
93	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. <i>Nature Medicine</i> , 2015 , 21, 1163-71	50.5	275
92	In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging. <i>Analytical and Bioanalytical Chemistry</i> , 2015 , 407, 8321-31	4.4	24
91	The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. <i>Gut</i> , 2015 , 64, 1936-48	19.2	100
90	Analysis of U2 small nuclear RNA fragments in the bile differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. <i>Digestive Diseases and Sciences</i> , 2014 , 59, 1436-41	4	14
89	A microRNA-based test improves endoscopic ultrasound-guided cytologic diagnosis of pancreatic cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1717-23	6.9	27
88	Induction of pancreatic cancer cell migration by an autocrine epidermal growth factor receptor activation. <i>Experimental Cell Research</i> , 2014 , 326, 307-14	4.2	14
87	Lentiviral overexpression of miRNAs. <i>Methods in Molecular Biology</i> , 2014 , 1095, 177-90	1.4	8
86	Circulating U2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer. <i>Clinical Chemistry</i> , 2014 , 60, 206-13	5.5	52
85	Suppression of soluble adenylyl cyclase protects smooth muscle cells against oxidative stress-induced apoptosis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2014 , 19, 1069.	-7594	16
84	Automated identification of subcellular organelles by coherent anti-stokes Raman scattering. <i>Biophysical Journal</i> , 2014 , 106, 1910-20	2.9	38
83	The pancreatic expression database: recent extensions and updates. <i>Nucleic Acids Research</i> , 2014 , 42, D944-9	20.1	22
82	Quantitative RT-PCR specific for precursor and mature miRNAs. <i>Methods in Molecular Biology</i> , 2014 , 1095, 121-34	1.4	5
81	New insights in the composition of extracellular vesicles from pancreatic cancer cells: implications for biomarkers and functions. <i>Proteome Science</i> , 2014 , 12, 50	2.6	42
80	A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding. <i>PLoS ONE</i> , 2014 , 9, e90461	3.7	17
79	U2 Small Nuclear RNA as a Biomarker in Cancer 2014 , 1-15		
78	Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. <i>Cell and Tissue Research</i> , 2013 , 351, 85-98	4.2	124

(2011-2013)

77	, 2013 , 319, 1744-1758	4.2	18
76	Small molecule inhibition of the KRAS-PDElInteraction impairs oncogenic KRAS signalling. <i>Nature</i> , 2013 , 497, 638-42	50.4	460
75	Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. <i>Gut</i> , 2013 , 62, 1034-43	19.2	59
74	Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. <i>International Journal of Cancer</i> , 2013 , 132, E48-57	7.5	108
73	EU Pancreas: an integrated European platform for pancreas cancer researchfrom basic science to clinical and public health interventions for a rare disease. <i>Public Health Genomics</i> , 2013 , 16, 305-12	1.9	1
7 ²	Keratin23 (KRT23) knockdown decreases proliferation and affects the DNA damage response of colon cancer cells. <i>PLoS ONE</i> , 2013 , 8, e73593	3.7	24
71	Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. <i>PLoS ONE</i> , 2013 , 8, e66371	3.7	31
70	Expression of microRNAs in basal cell carcinoma. <i>British Journal of Dermatology</i> , 2012 , 167, 847-55	4	150
69	MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma. <i>Journal of Neuro-Oncology</i> , 2012 , 109, 239-44	4.8	58
68	Microarray analysis of microRNA expression in cutaneous squamous cell carcinoma. <i>Journal of Dermatological Science</i> , 2012 , 68, 119-26	4.3	89
67	MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL. <i>Carcinogenesis</i> , 2012 , 33, 732-9	4.6	141
66	Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2012 , 131, E86-95	7.5	84
65	Lack of CCR7 expression is rate limiting for lymphatic spread of pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2012 , 131, E371-81	7.5	23
64	Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. <i>Neuro-Oncology</i> , 2012 , 14, 29-33	1	144
63	Microcapsules: Reverse Sonoporation and Long-lasting, Safe Contrast. <i>Acoustical Imaging</i> , 2012 , 81-90		2
62	Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. <i>Blood</i> , 2011 , 117, 3140-6	2.2	248
61	Keratin 23, a novel DPC4/Smad4 target gene which binds 14-3-3\(\partial BMC \) Cancer, 2011 , 11, 137	4.8	21
60	A novel organometallic ReI complex with favourable properties for bioimaging and applicability in solid-phase peptide synthesis. <i>ChemBioChem</i> , 2011 , 12, 371-6	3.8	57

59	MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B. <i>Laboratory Investigation</i> , 2011 , 91, 1472-9	5.9	98
58	The Pancreatic Expression database: 2011 update. <i>Nucleic Acids Research</i> , 2011 , 39, D1023-8	20.1	28
57	Repression of KIAA1199 attenuates Wnt-signalling and decreases the proliferation of colon cancer cells. <i>British Journal of Cancer</i> , 2011 , 105, 552-61	8.7	72
56	Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-prone families. <i>Clinical Genetics</i> , 2010 , 77, 333-41	4	23
55	Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010 , 29, 21	12.8	16
54	Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families. <i>Familial Cancer</i> , 2010 , 9, 335-43	3	40
53	Gene expression analysis of cell death induction by taurolidine in different malignant cell lines. <i>BMC Cancer</i> , 2010 , 10, 595	4.8	8
52	Manual microdissection combined with antisense RNA-longSAGE for the analysis of limited cell numbers. <i>Methods in Molecular Biology</i> , 2010 , 576, 135-54	1.4	3
51	Detection of clonal T cells in the circulation of patients with nephrogenic systemic fibrosis. <i>Archives of Dermatology</i> , 2009 , 145, 1164-9		7
50	Clonal T-cell populations are frequent in the skin and blood of patients with systemic sclerosis. <i>British Journal of Dermatology</i> , 2009 , 161, 785-90	4	13
49	Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation. <i>Journal of Proteome Research</i> , 2009 , 8, 1647-56	5.6	59
48	Pancreatic intraepithelial neoplasia revisited and updated. <i>Pancreatology</i> , 2009 , 9, 45-54	3.8	82
47	A web-based platform for mining pancreatic expression datasets. <i>Pancreatology</i> , 2009 , 9, 340-3	3.8	6
46	Divergent mechanisms underlie Smad4-mediated positive regulation of the three genes encoding the basement membrane component laminin-332 (laminin-5). <i>BMC Cancer</i> , 2008 , 8, 215	4.8	11
45	Application of fluorescence dye saturation labeling for differential proteome analysis of 1,000 microdissected cells from pancreatic ductal adenocarcinoma precursor lesions. <i>Methods in Molecular Biology</i> , 2008 , 425, 1-14	1.4	6
44	Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. <i>Clinical Chemistry</i> , 2008 , 54, 1716-24	5.5	173
43	Monitoring and modeling of microbubble behavior during ultrasound mediated transfection of cell monolayers 2008 ,		3
42	Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. <i>International Journal of Colorectal Disease</i> , 2008 , 23, 1033-9	3	58

(2004-2007)

41	MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. <i>Oncogene</i> , 2007 , 26, 4442-52	9.2	552
40	High-level inducible Smad4-reexpression in the cervical cancer cell line C4-II is associated with a gene expression profile that predicts a preferential role of Smad4 in extracellular matrix composition. <i>BMC Cancer</i> , 2007 , 7, 209	4.8	7
39	Discarding duplicate ditags in LongSAGE analysis may introduce significant error. <i>BMC Bioinformatics</i> , 2007 , 8, 92	3.6	7
38	Pancreatic Expression database: a generic model for the organization, integration and mining of complex cancer datasets. <i>BMC Genomics</i> , 2007 , 8, 439	4.5	34
37	Differential proteome analysis of colon carcinoma cell line SW480 after reconstitution of the tumour suppressor Smad4. <i>Analytical and Bioanalytical Chemistry</i> , 2006 , 386, 1603-12	4.4	5
36	Anticipation in familial pancreatic cancer. <i>Gut</i> , 2006 , 55, 252-8	19.2	89
35	Evaluation of the 4q32-34 locus in European familial pancreatic cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 1948-55	4	45
34	Low frequency of CHEK2 mutations in familial pancreatic cancer. Familial Cancer, 2006, 5, 305-8	3	27
33	Genetics of hereditary pancreatic carcinoma. Clinics in Laboratory Medicine, 2005, 25, 117-33	2.1	3
32	HNPCC-associated small bowel cancer: clinical and molecular characteristics. <i>Gastroenterology</i> , 2005 , 128, 590-9	13.3	154
31	Smad4 deficiency in cervical carcinoma cells. <i>Oncogene</i> , 2005 , 24, 810-9	9.2	28
30	Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. <i>Oncogene</i> , 2005 , 24, 6626-36	9.2	161
29	RNASEL germline variants are associated with pancreatic cancer. <i>International Journal of Cancer</i> , 2005 , 117, 718-22	7.5	34
28	Application of fluorescence difference gel electrophoresis saturation labelling for the analysis of microdissected precursor lesions of pancreatic ductal adenocarcinoma. <i>Proteomics</i> , 2005 , 5, 2665-79	4.8	114
27	aRNA-longSAGE: a new approach to generate SAGE libraries from microdissected cells. <i>Nucleic Acids Research</i> , 2004 , 32, e131	20.1	26
26	Where and when does pancreatic carcinoma start?. <i>Medizinische Klinik</i> , 2004 , 99, 191-5		6
25	Tumor suppressor Smad4 mediates downregulation of the anti-adhesive invasion-promoting matricellular protein SPARC: Landscaping activity of Smad4 as revealed by a "secretome" analysis. <i>Proteomics</i> , 2004 , 4, 1324-34	4.8	38
24	HNPCC: six new pathogenic mutations. BMC Medical Genetics, 2004, 5, 16	2.1	2

23	Prevalence of familial pancreatic cancer in Germany. <i>International Journal of Cancer</i> , 2004 , 110, 902-6	7.5	66
22	Genetics of hereditary pancreatic carcinoma. <i>Gastroenterology Clinics of North America</i> , 2004 , 33, 919-34, ix	4.4	3
21	The NOD2 3020insC Mutation and The Risk of Familial Pancreatic Cancer?. <i>Hereditary Cancer in Clinical Practice</i> , 2004 , 2, 149-150	2.3	13
20	Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine. <i>Cancer</i> , 2003 , 98, 1774-5; author reply 1775-6	6.4	1
19	BRCA2 germline mutations in familial pancreatic carcinoma. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 214-21	9.7	388
18	SMIF, a Smad4-interacting protein that functions as a co-activator in TGFbeta signalling. <i>Nature Cell Biology</i> , 2002 , 4, 181-90	23.4	80
17	CDKN2A germline mutations in familial pancreatic cancer. <i>Annals of Surgery</i> , 2002 , 236, 730-7	7.8	122
16	German national case collection of familial pancreatic cancer - clinical-genetic analysis of the first 21 families. <i>Oncology Research and Treatment</i> , 2002 , 25, 262-6	2.8	15
15	Molecular pathogenesis of pancreatic cancer. <i>Hematology/Oncology Clinics of North America</i> , 2002 , 16, 17-35, v	3.1	7
14	Pankreaskarzinom 2002 , 187-206		
13	Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. <i>American Journal of Pathology</i> , 2001 , 158, 1677-83	5.8	191
12			
	Update of familial pancreatic cancer in Germany. <i>Pancreatology</i> , 2001 , 1, 510-6	3.8	30
11	Update of familial pancreatic cancer in Germany. <i>Pancreatology</i> , 2001 , 1, 510-6 Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 9624-9	3.8	30
11	Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. <i>Proceedings of the</i>	11.5	
	Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 9624-9	11.5	221
10	Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 9624-9 Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. <i>Oncogene</i> , 1999 , 18, 2367-7 DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced	11.5 1 9.2	221
10	Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 9624-9 Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. <i>Oncogene</i> , 1999 , 18, 2367-7 DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression. <i>Oncogene</i> , 1999 , 18, 3152-8 The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior	11.5 1 9.2 9.2	221 111 71

LIST OF PUBLICATIONS

5	DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. <i>Science</i> , 1996 , 271, 350-3	33.3	1928
4	Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. <i>Nature Genetics</i> , 1996 , 13, 343-6	36.3	524
3	Molecular genetics of exocrine pancreatic neoplasms. Surgical Clinics of North America, 1995, 75, 857-69	94	50
2	Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 5950-4	11.5	136
1	Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. <i>Nature Genetics</i> , 1994 , 8, 27-32	36.3	980